// App-Quantinova.ai

513 : Efficacy results of a phase 1b study of ont-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.

Researchers

Presenter

  • Virginia F. Borges

Principal Investigators

  • Cristiano Ferrario

  • Nathalie Aucoin

  • Carla Isadora Falkson

  • Qamar J. Khan

  • Ian E. Krop

  • Stephen Welch

  • Philippe L. Bedard

  • Alison Katherine Conlin

  • Jorge Chaves

  • Luke N. Walker

  • Erika Paige Hamilton

Medical Centers

  • University of Colorado Cancer Center, Aurora, CO

  • Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada

  • Hopital Cite de la Sante de Laval, Laval, QC, Canada

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • University of Kansas Medical Center, Kansas City, MO

  • Dana-Farber Cancer Institute, Boston, MA

  • London Regional Cancer Centre, London, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Providence Cancer Center Oncology and Hematology Care Clinic, Portland, OR

  • Northwest Medical Specialists PLLC, Tacoma, WA

  • Oncothyreon, Seattle, WA

  • Sarah Cannon Research Institute/Tennessee Oncology, Brentwood, TN

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Brain metastasis

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

  • ONT380

  • taxane

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02025192

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved